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A Fast Fourier Transform method for calculating the three-dimensional dose rate distribution for murine, 
human-tumor xenografts is outlined. The required input includes evenly-spaced activity slices which span 
the tumor. Numerical values in these slices are determined by quantitative “‘1 autoradiography. For the 
absorbed dose-rate calculation, we assume the activity from both “‘I- and WY-labeled radiopharmaceu- 
ticals would be distributed as is measured with the ‘251 label. Two example cases are presented: an 
ovarian-carcinoma xenograft with an IgG 2ak monoclonal antibody and a neuroblastoma xenograft with 
meta-iodobenzylguanidine (MIBG). 
Considering all the volume elements in a tumor, we show, by comparison of histograms and also relative 
standard deviations, that the measured ‘251 activity and the calculated 13’1 dose-rate distributions, are 
similarly non-uniform and that they are more non-uniform than the calculated WY dose-rate distribution. 
However, the maximum-to-minimum ratio, another measure of non-uniformity, decreases by roughly an 
order of magnitude from one distribution to the next in the order given above. 
Introduction 
For tumor dosimetry, one would ideally have re- 
peated, high-resolution, tomographic images so that 
the entire timesourse of activity uptake and washout 
could be observed for individual voxels of interest. 
The three-dimensional distribution of absorbed 
dose up to any point could then be calculated within 
the tumor to high accuracy from known physical 
information. 
Lacking such imaging both for patients and also 
for animal models, one can use autoradiography of 
excised tumors. In therapy of murine tumors, the 
autoradiographs can provide the activity distribution 
at a particular time point-the time of tumor re- 
moval. It is then possible to calculate the distribution 
of dose rate at that time point. 
We previously published, in an abstract for the 
36th Annual Meeting of the Society of Nuclear Medi- 
cine (Koral et al., 1989), preliminary results that used 
point dose kernels and the Fast Fourier Transform 
with a single autoradiograph slice to calculate the 
three-dimensional dose rate for murine human-tumor 
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xenografts. At the meeting itself, we presented the 
three-dimensional dosimetry method but based on 
serial autoradiographs. Another group subsequently 
published an abstract (Roberson et al., 1990) and full 
paper (Roberson et al., 1992) on three-dimensional 
dose calculation from serial autoradiographs with 
the same point dose kernels but without use of the 
Fast Fourier Transform. Two other groups separ- 
ately derived their own point dose kernels for dosim- 
etry calculations (Leichner et al., 1989; Lui et al., 
1991). 
Implantation of miniature thermoluminescent 
dosimeters (TLDs) in mouse tumors (Griffith et al., 
1988) can add further three-dimensional information 
by recording the absorbed dose up to the time of 
sacrifice at individual spatial locations. However, 
drawbacks are (1) assuming that the dosimeters do 
not perturb the radiation field in the tumor and (2) 
error from inferring the absorbed dose at other 
spatial locations. One such previous study by 
Griffith et al. (1988) actually used TLD measure- 
ments in conjunction with autoradiographs. The au- 
toradiographs showed large variations in 13’1 activity 
at sacrifice for the xenograft of a Raji B-cell 
lymphoma in an athymic mide mouse with the la- 
beled LYM-1 monoclonal antibody (Mab) (Griffith 
et al., 1988). The activity at sacrifice for a LS174T 
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colorectal-carcinoma system with B72.3 Mab 
appeared to be similarly non-uniform. 
The B-cell-lymphoma TLD measurements corre- 
sponding to twenty volume elements gave a pre- 
sacrifice absorbed dose that ranged from 392 to 
1640cGy, a maximum-over-minimum ratio of 4.2. 
Fading of the TLD light output over time was 
presumably a problem with these measurements. 
Strand et al. (1992) have shown that such fading can 
reduce the signal to “one third of its original value” 
over 9 days with the TLD in muscle tissue. [See a 
general review of animal TLD measurement in Yorke 
et al. (1993).] We are interested only in the ratio of 
maximum-to-minimum absorbed dose for a compari- 
son to our computed results. As long as fading was 
the same fraction for both the high- and the low-dose 
TLD, our discussion would not be affected. The 
twenty regions sampled by TLD in the colorectal- 
carcinoma system gave a range of 330-8 10 cGy which 
yields a somewhat smaller ratio of 2.5. 
Our purpose in this paper is to present our method, 
based on the Fast Fourier Transform, for three-di- 
mensionally calculating the distribution of absorbed 
dose-rate at the time of sacrifice. We use two xeno- 
graft models, both different from those investigated 
by Griffith et al. (1988) and from that investigated by 
Roberson et al. (1992), as relatively independent 
examples. We are able to mathematically characterize 
the degree of non-uniformity of the different distri- 
butions over all the volume elements in a tumor as 
does Roberson et al. (1992). That study employs a 
differential dose-rate histogram; we employ three 
different descriptors of non-uniformity. Specifically, 
we compare the distribution of absorbed dose-rate 
with 13’1 to the distribution of “‘1 activity concen- 
tration because we are interested in how accurately 
one can infer 13’1 dose-rate non-uniformity simply by 




(1) We first investigated a human ovarian-carci- 
noma (HTB 77 IP3) xenograft in a female nu/nu 
homozygous CD1 mouse. The nude mouse was 
injected subcutaneously with a single-cell suspension 
of 10 x lo6 cells. The tumor was allowed to develop 
and grow over 21 days. Then, 3.7MBq (5pg) of 
L251-labeled 566.4, which is an IgG2ak murine mono- 
clonal antibody reactive with epithelial carcinoma 
(Wahl et al., 1986), was injected intraperitoneally. 
The intraperitoneal route of administration was of 
interest for this system. The mouse was sacrificed 6 
days later. This relatively long time after injection 
was chosen because we were interested in tumor- 
specific binding and it predominates then (Wahl et al., 
1988). 
(2) We then studied a human-Meyers-neuroblas- 
toma xenograft in a female nu/nu homozygous CD1 
mouse. The animals were inoculated with minced 
tumor as previously described (Sisson et al., 1991). 
When the tumor reached a diameter of approx. 1 cm, 
the mouse was injected with 74 MBq of “‘1 meta- 
iodobenzylguanidine (MIBG). After 6.5 h, the animal 
was sacrificed and the tumor excised. 
Autoradiography of sample and standards 
Excised tumors were handled by quickly freezing at 
- 70°C (ovarian carcinoma) or by dipping the tissue 
for 45-60 s in iso-pentane cooled with liquid nitrogen 
(neuroblastoma). Frozen tissues were kept at -70°C 
until used, then attached to the cryostat holder with 
OCT (Miles Scientific, Naperville, Ill.) at - 30°C and 
sectioned at - 15 to -20°C. The frozen sections, 
which were 12 pm thick (ovarian carcinoma) or 
10pm thick (neuroblastoma), were picked up on 
microscope slides, with as little rotation relative to 
one another as possible, and air dried at room 
temperature. Contact autoradiography for the sec- 
tions was performed by parallel positioning of these 
slides face down on standard sheets of Kodak XARS 
film in a cassette with an intensifying screen. For 
sections of ovarian carcinoma, the film was exposed 
for 64 h at room temperature; for sections of neuro- 
blastoma, exposure was at - 70°C for 2 h. The latter 
is a shorter procedure which we believe to be equally 
good. 
Standards for film calibration were prepared from 
the livers of balb-C mice. For the ovarian xenograft, 
the mouse was injected with 3.7 MBq of the ‘*‘I 566.4 
preparation. The liver was removed, weighed, 
counted in a y counter, frozen and sectioned at the 
same thickness as the tumor samples. To obtain seven 
calibration points, a single slice was placed on each 
of the seven microscope slides. These were arranged 
on the same sheet of film as the tumor. It was 
assumed that the liver had a uniform concentration 
of activity. This assumption of uniformity was indi- 
cated by the results of the autoradiography for the 
individual liver slices. The total counts for the liver 
were converted to MBq by a known calibration 
constant in units of MBq/counts. The value for the 
activity concentration of the liver, a, in MBq/g was 
obtained by dividing by the mass. To obtain effective 
values of MBq/g for individual liver slices which were 
different by a factor of 2, slice one was removed from 
the film after 2 h, slice two after 4 h, slice three after 
8 h etc. up to slice seven after 128 h. Since the tumor 
samples exposed the film for 64 h the individual slices 
of the standard had effective values of activity con- 
centration equal to (tJ64)*a where t, are the times in 
hours given above (1 < i < 7). This last step is suffi- 
cient because (1) the standards and samples are the 
same thickness and (2) film exposure is to be related 
to microcuries/gram. The procedure is only correct to 
first order because of decay but has little error (1.5% 
for the worst point) because of the long half life of ‘*‘I 
(60.2 days) relative to the exposure times used. For a 
radioisotope with a shorter half life and the same 
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exposure times, it would be necessary to do the 
calibration with optical density plotted against cumu- 
lated activity concentration (kBq h/mg) as in Jiinsson 
et al. (1992). 
For the neuroblastoma xenograft a different pro- 
cedure was chosen to obtain standards of the same 
thickness as the tumor samples: liver sections from 
animals injected with 0.93, 1.85, 3.7, 7.4, 14.8 and 
22.2 MBq of “‘1 MIBG exposed the film being used 
for the tumor. This procedure required the additional 
assumption of similar uptake by the six mice used. 
Essentially, we took a new calibration because of the 
changed exposure conditions and also arbitrarily 
chose a new method for obtaining standards. 
Quantitative analysis of autokzdiographs 
The autoradiographs were evaluated by a 
videodensitometric system. The light intensity pass- 
ing through the film from a uniform source was 
evaluated and digitized (O-255) as a function of 
position using a video camera*, lens? and computer$. 
The darkest section of film was set to have a value of 
0 and the least exposed to have a value of 255. A 
normalization process assured that there was equal 
sensitivity across the film. The digital value, Z, for the 
intensity of light passing through an arbitrary pixel of 
the autoradiogram was then related to the highest 
intensity, 255, to compute the film optical density, D, 
as follows: 
log,,&= -D 
In this way, the average digital value for each stan- 
dard was found and converted to an optical density. 
As is customarily done, a plot of optical density 
versus activity concentration was made for the seven 
standards. The functional form of a cubic polynomial 
was fit to these data as shown in Fig. 1. From this 
form, the computed optical density of each pixel in 
the tumor sample was converted to a calculated 
activity concentration which was stored for further 
processing. 
12jI data 
The original form of the “‘1 data for the ovarian 
xenograft involved 19 slices, evenly spaced every 
0.6 mm. Tumor longitudinal extent was 1.08 cm. A 
square 87 x 87 pixel array was sufficient to cover all 
slices; the pixel size was 244 ,um square. For the 
neuroblastoma xenograft, the original form of the 
data was 9 slices, evenly spaced every millimeter. 
Tumor longitudinal extent was 0.80 cm. A 52 x 68 
pixel array was used; the pixel size was 276 pm 
square. The thickness, spacing and pixel-size differ- 
ences between examples were small and mostly arbi- 
trary. Individual slices of each tumor were assumed 
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Fig. 1. Plot of average film optical density vs calculated 
activity-concentration for the seven standards employed for 
the ovarian-carcinoma xenograph. Also shown is the poly- 
nomial fit which allows the optical density for a pixel in the 
tumor autoradiograph to be associated with an activity- 
concentration. 
to be properly resgistered with each other after 
visually locating the centroid of each slice at the same 
location. 
Three-dimensional absorbed dose-rate calculation 
A dose-rate distribution was calculated for an 
‘311-labeled compound by assuming that the activity 
distribution would be that of the ‘251-labeled com- 
pound which seemed quite reasonable. A dose-rate 
distrubtion for “Y was calculated by making the 
same assumption, although labeling MIGB with 9oY 
was unlikely. The results in this case are mainly a 
second demonstration of the effects of the longer- 
range /J-particle of 9oY. 
The two sets of multiple-slice “‘1 activity-concen- 
tration data, one for each tumor system, were ana- 
lyzed using a program, TDRD, on a Digital VAX 
8300 computer. The program calculated the three- 
dimensional dose-rate distribution, D(x, y, z), in a 
homogeneous water-equivalent medium resulting 
from the specified activity-concentration distribution 
A (x, y, z) using a Fast Fourier Transform approach. 
Applications of an earlier version of TDRD in the 
calculation of D(x, y, z) for radially-symmetrical 
activity-concentration distributions have been 
described previously (Kwok et al., 1985). In the 
earlier version, Loevinger’s B-point-source dose func- 
tion (Loevinger et al., 1956) was used, while in the 
present version of TDRD the B-dose point kernels 
derived from Monte Carlo calculations of electron 
transport in water were incorporated (Prestwich ct 
al., 1989) to increase accuracy. 
To input a non-symmetrical A (x, y, z) into the 
program, the distribution had to be digitized into 
evenly-spaced 64 x 64-pixel activity-concentration 
slices, Ai(x, y), 1 < i ,< 32. The number of slices had 
to be a power of 2. Consequently, the 19 slices of the 
ovarian xenograft activity-concentration data were 
interpolated longitudinally to 32 evenly-spaced ac- 
tivity-concentration slices. The original 87 x 87 
matrix size for each slice was reduced in resolution in 
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both x and y directions by summing every four 
neighboring pixels into one. For the neuroblastoma 
xenograft, the original 9 slices were interpolated 
longitudinally to give 16 evenly-spaced Ai(x, y). The 
original 52 x 68 matrix size for each Ai& y) was 
reduced in resolution by a factor of two in the second 
direction. The three-dimensional Fourier transform 
of the reformatted activity-concentration data was 
then evaluated together with the three-dimensional 
Fourier transform of the dose point kernel of the 
radionuclide either 9oY or “‘I. After multiplying the 
two Fourier’ transforms and evaluating the inverse 
Fourier transform of the product, D(x, y, z) was 
calculated. For each of the two radionuclides, 
D(x, y, z) was output into a disk file slice by slice in 
both graphical and numerical form. 
0 
start 
A flow chart of the general program appears in 
Fig. 2. Note that a subroutine USRAD, can still be 
used to generate hypothetical, radially-symmetric, 
activity distributions. This provision was not em- 
ployed in this paper. Also note that if the activity 
distribution is digitized to a resolution that is greater 
than 32 x 32, then a subroutine, SPLIT, is called to 
divide the activity-concentration matrix into sub- 
matrices and appropriate steps are followed. 
It should be pointed out that photon doses from 
13’1 were not included because they would contribute 
less than several percent of the beta doses for tumor 
volumes less than a few centimeters in diameter. The 
accuracy of TDRD has been checked indirectly 
against phantom studies (Wessels et al., 1986) and 
directly against other computational methods 
call MATDIM 
for matrix size 
$ 
call GENDAT for 
radiation type 
calculate factor ‘y 
1 call SPLIT 
Fig. 2. Flow chart of three-dimensional absorbed dose-rate program. Note that F.T. refers to the Fast 
Fourier Transform and DPK stands for dose point kernel. 
Figs 3 (top) and 4 (bottom). Captions on p. 906. 
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Fig. 5. Comparison of three distributions for the 18th plane of the ovarian-carcinoma xenograft shown 
in Fig. 3. The activity distribution measured with lzsI and the dose-rate distribution calculated for the 
B-emissions from “‘I are almost equally non-uniform. The non-uniformity is reduced assuming labeling 
with %Y. The color scale is independently related to the values in the particular distribution. 
(Werner et al., 1988). In the first study, TLD fading uniform distribution would be represented by two 
may have distorted the results. bars of equal height at 0.8-1.0 and 1.0-1.2. 
Characterization of distributions 
We characterized a multi-plane distribution in 
three ways: (1) by the ratio of the largest value 
divided by the smallest, (2) by a histogram of values 
and (3) by a single statistic representing non-uniform- 
ity. The determination of the tumor edge was done by 
including all non-zero values in the activity-concen- 
tration distribution. All voxels within the edge were 
then checked to find the largest and smallest values 
and the ratio of these values was computed. Also the 
average value over all voxels was found. To calculate 
a histogram, bar width was set at 0.2 of the average 
value. Then, the number of voxels within each range 
(O&O).2 times average, 0.2-0.4 times average etc) was 
found. Values for bars which were beyond 2.0 times 
average were not plotted for convenience. A very 
For the single statistic, we chose relative standard 
deviation (also called coefficient of variation), that is, 
the standard deviation divided by the mean. This 
value is directly proportional to non-uniformity and 
has a smallest possible value of zero. That is, if all 
voxels had exactly the same value (no non-uniform- 
ity), the standard deviation and, thus, the relative 
standard deviation would be zero. The maximum 
value was finite but unlimited. 
Results 
The 32-plane result of longitudinal interpolation 
for the human-ovarian-cancer xenograft is shown in 
Fig. 3. It is Seen that the region of highest activity 
concentration changes location as one advances from 
plane to plane. No single slice has uniform activity 
Fig. 3 (p. 905, top). Distribution of activity-concentration for the ovarian-cancer xenograft after 
interpolation. Spacing is 348 pm. The color scale is related to the activity-concentration of the slices as 
a group. That is, a given color represents the same activity-concentration in each slice. The slice sequence 
is left to right, top to bottom. 
Fig. 4 (p. 905, bottom). Distribution of activity-concentration for the neuroblastoma xenograft after 
interpolation. Spacing is 530 pm. Color scale and slice sequence as in Fig. 3. 
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concentration. The ratio of maximum pixel value 
over minimum pixel value is given in Table 1. 
The 16-plane result of interpolation for the neuro- 
blastoma-tumor xenograft is shown in Fig. 4. 
Here some of the individual slices appear fairly 
uniform in their activity concentration, although the 
level can change sharply over only a one-slice differ- 
ence. The maximum to minimum ratio is given in 
Table 1. 
For the plane approximately mid-way from the 
ends of the ovarian-carcinoma tumor (plane number 
18 out of 32), Fig. 5 shows the ‘25I activity-concen- 
tration distribution as well as the calculated 13’1 
dose-rate and 9oY dose-rate distributions. The “‘1 
activity-concentration distribution appears to be only 
slightly more non-uniform than the 13’1 dose-rate. 
The 9oY dose-rate appears to be the least non- 
uniform. 
A histogram comparison of the same three distri- 
butions, but for the entire tumor rather than a single 
plane, is given in Fig. 6. There are more values at the 
lowest extreme for the activity-concentration than for 
either dose-rate distribution and also more with “‘I 
than with “Y. 
As given in Table 1, there is a maximum-to- 
minimum ratio of 120 for the 13’1 dose-rate distri- 
bution, and one of 15.4 for the 9oY dose-rate 
distribution. The change is roughly an order of 
magnitude as is the change between ‘25I activity and 
13’1 dose-rate. 
For the neuroblastoma xenograft (not shown) 
there are again more values at the lowest extreme for 
the activity-concentration than for either dose-rate 
distribution and also more with 13’1 than with 9oY. 
The number of voxels between 0 and 0.2 of the mean 
are 9.7, 6.5 and 0.0% of all voxels, respectively. For 
the activity-concentration and for absorbed dose-rate 
with “‘I, the distribution is skewed: the highest bars 
are for the ranges slightly greater than the mean. For 
absorbed dose-rate with “Y, the distribution is more 
symmetric. The maximum-to-minimum dose-rate 
ratios are given in Table 1. 
Relative standard deviation is given in Table 2. 
For the ‘25I activity distribution, it is 65.7% for 
the ovarian-carcinoma tumor and 48.0% for the 
neuroblastoma tumor. (The ovarian activity is thus 
more non-uniform.) The non-uniformity decreases as 
one changes from activity-concentration to 13’1 dose- 
rate and finally to “Y-dose-rate. The same trend 
appeared in the single ovarian-carcinoma slice in 
Fig. 5. 
Table I. Ratio of maximum pixel value wer minimum pixel 
value for specified distribution in ovarian and neuroblastoma 
xenografts 
Ratio of Maximum-over-minimum 
Distribution 
“‘1 activity-concentration 
“‘I absorbed dose-rate 






We have found the activity-concentration distri- 
bution of two tumor-xenograft systems, ovarian car- 
cinoma and neuroblastoma, to be non-uniform. Such 
was also the case for the normal rat kidney using an 
“‘In-labeled anti CEA-F(ab’), monoclonal antibody 
(Jbnsson et al., 1992). It was also the case for the 
tumor systems investigated by Griffith et al. (1988) 
for lymphoma and colorectal carcinoma. However, 
early after injection, our neuroblastoma results do 
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Fig. 6. Histogram comparison of three distributions over all 
the volume elements in the ovarian-carcinoma xenograft: 
the lzsI activity-concentration (a), the 13’1 dose-rate distri- 
bution (b), and the wY dose-rate distribution (c). The 
number of voxels within a range is plotted against the 
midpoint of the range. Each midpoint is a fraction of the 
mean value for the entire tumor. In (a), (b) and (c) respect- 
ively, 1856, 1466 and 243 voxels lie beyond twice the average 
and are not plotted. 
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as was the case with LS147T human-colon-cancer 
xenografts with ‘)‘I-labeled 17-1A Mab (Roberson 
et al., 1992). 
We have demonstrated that the dose-rate distri- 
bution with 13’1 is similar to that for the 1251 activity- 
concentration except as characterized by the 
maximum-to-minimum ratio. This ratio reflects the 
range of the distribution. It has practical importance, 
for example, when one is concerned that all voxels 
receive at least some lower limit of radiation absorbed 
dose. However, since the ratio is determined by the 
values in only two voxels, error in these values can 
distort its value. In this respect, one could, perhaps, 
derive more use from an average-to-minimum ratio 
since it sould be more error-resistant. The general 
similarity in the two distributions, excluding the 
maximum-to-minimum ratio, is not surprising given 
that the range of the 13’1 b-particle and the imaging 
resolution are similar. 
In the case of the ovarian-carcinoma xenograft, 
results for a middle plane in the tumor show the 9oY 
dose-rate to be the least non-uniform. This result is 
expected given the relatively long range of the 9oY 
b-particle. It also is consistent with the calculated 
results for a 2 x 2 mm region in a Raji B-cell tumor: 
Fig. 11 (13’1), compared to Fig. 12 (9”Y) in Griffith 
et al. (1988). In their calculation, however, the results 
at the edges may be incorrectly low because the 
activity outside the region was neglected. Moreover, 
a measured, three-dimensional activity distribution 
was not used; rather, the measured activity of the 
plane of interest was simply replicated above and 
below that plane. 
For the dose-rate distribution from 13’1 at the time 
of sacrifice, the maximum-over-minimum ratio is 
188 for the ovarian carcinoma system and 120 for 
the neuroblastoma xenograft. These values are 
much larger than the pre-sacrifice absorbed-dose 
maximum-to-minimum ratios calculated from the 
TLD samples published by Griffith et al. (1988). 
Recall their observed ratios of 4.2 for B-cell 
lymphoma and 2.5 for colorectal carcinoma. We 
sampled 21,994 and 9698 voxels in the ovarian and 
neuroblastoma xenografts, respectively, however, 
while they sampled only 20 locations in each of their 
systems. The much greater number of samples makes 
finding a much larger maximum-to-minimum ratio 
more likely, if it physically exists. 
There is one methodological point to discuss: the 
question of whether the three-dimensional regis- 
tration was accurate. A procedure for registering 
Table 2. Relative standard deviation* for specified distributions in 
ovarian and neuroblastoma xenografts 
Relative standard deviation 
Distribution Ovarian Neuroblastoma 
“‘1 activity-concentration 65.7% 48.0% 
‘“‘I absorbed dose-rate 60.1 45.6 
‘9 absorbed dose-rate 43.5 38.5 
*A greater value implies more non-uniformity. 
both the horizontal and vertical centroids of all 
the slices could easily be automated. However, 
this would not necessarily yield the true three- 
dimensional orientation. Obtaining that orienta- 
tion would probably require two marker “wires” 
which could be inserted through the tumor without 
distorting it but yet be cut by the microtome. 
Even then, one cannot be sure of retaining the in vivo 
shape of the tumor, so the problem remains, to some 
extent, unless one achieves high-resolution in vivo 
imaging. 
We note that our three-dimensional dose-rate com- 
puter program appears faster than that of reference 
(Roberson et al., 1992) because we use the Fast 
Fourier Transform. They report that calculation of a 
three-dimensional dose-rate distribution on a grid of 
200 pm takes approx. 100 h on a VAX 8800 com- 
puter whereas we calculated both the 13’1 and the 9oY 
dose-rate distributions on a grid of 550 pm in 30 min 
on a VAX 8300. Their finer grid accounts for some, 
but not all, of the time difference. They acknowledge 
that use of the Fast Fourier Transform would reduce 
their calculation time. 
Also, our program can produce absolute values. 
This fact is fairly clear as an extension of the results 
of Kwok et al. (1985). We have not presented nor 
made explicit use of that capability here. 
Lastly, the problem of obtaining all the dosimetry 
information from a tumor which has taken up radio- 
activity still remains, as we mentioned in the Intro- 
duction. It will probably wait on the development of 
new, high-resolution, small-animal tomographs (see 
Rogers et al., 1993; Green et al., 1992) as does 
solution of the registration problem. Other comments 
on the general dosimetric problem can be found in a 
recent editorial by Roberson (1992). 
Summary 
As detailed in the text, our absorbed dose-rate 
calculations are based on the assumption that, with 
13’1 labeling as well as 9oY labeling, the activity 
distribution will be the same as with “‘1 labeling. 
Within that assumption, our results show: (1) that 
with 13’1, the general non-uniformity of the activity 
distribution is similar to the general non-uniformity 
of the dose-rate distribution; (2) that the goY dose-rate 
distribution is generally more uniform than either 
the activity distribution or the 13’1 dose-rate distri- 
bution; and (3) that the ratio for the maximum- 
valued voxel over the minimum-valued voxel 
decreases by roughly an order of magnitude between 
the activity-concentration distribution and the 13’1 
dose-rate distribution and then again between the ‘)‘I 
and the 9oY dose-rate distributions. The first two 
results are new because they hold for distributions 
over all the volume elements in a tumor. They extend 
similar previous findings for single slices through a 
tumor. 
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